Treatment of Erdheim-Chester disease from the perspective in 2026
Authors:
prof. MUDr. Adam Zdeněk, CSc. 1; MUDr. Štork Martin, Ph.D. 1; doc. MUDr. Řehák Zdeněk, Ph.D. 2; MUDr. Boichuk Ivanna 1; prof. MUDr. Krejčí Marta, Ph.D. 1; prof. MUDr. Pour Luděk, Ph.D. 1
Authors‘ workplace:
Interní hematologická a onkologická klinika LF MU a FN Brno
1; Oddělení nukleární medicíny, MOÚ, Brno
2
Published in:
Klin Onkol 2026; 39(4): 255-261
Category:
Review
doi:
https://doi.org/10.48095/ccko2026255
Overview
Background: With the discovery of new drugs, treatment of Erdheim-Chester disease (ECD) is gradually evolving and changing. The text provides an overview of effective drugs available in 2026 for patients with ECD. Treatment options: We consider it appropriate to divide treatment into treatment targeting the inflammatory reaction induced by ECD, and treatment targeting malignant histiocytes. To suppress the inflammatory reaction, high doses of glucocorticoids can be used, but only short-term. For long-term suppression of the inflammatory reaction, anakinra is most commonly used. In rare cases, a similar effect has been reported with canakinumab, as well as with sirolimus and anti-TNF drugs. Anakinra is used both alone and in combination with other drugs. ECD cells, like histiocytosis cells from Langerhans cells, are derived from a monocytic lineage, which similarly to the lymphocytic lineage, is very sensitive to cladribine (2-chloro-2’-deoxyadenosine). This drug is the most effective cytostatic agent for patients with ECD. In several smaller clinical studies, the benefit of treatment with interferon alfa has been described. Thus, interferon alfa, despite its side effects, represents one of the treatment options. In cases of severe ECD and the presence of the BRAFV600E mutation, two drugs are recommended – vemurafenib and dabrafenib. For patients with a severe course without the BRAFV600E mutation, MEK kinase inhibitors trametinib and cobimetinib are recommended. The literature contains conflicting conclusions in studies evaluating the dependence of the effectiveness of these drugs on the detection of mutations in the MAPK signaling pathway. Targeted therapy is associated with numerous side effects, as well as the risk of relapse after its discontinuation. If the administered drugs trigger an inflammatory response, anakinra is again used to suppress it. Conclusion: Treatment of ECD always requires an assessment of the extent of the disease and degree of organ damage in order to choose the appropriate therapy.
Keywords:
anakinra – vemurafenib – dabrafenib – Erdheim-Chester disease – cladribine – cobimetinib – interferon alfa – trametinib
Sources
1. Goyal G, Heaney ML, Collin M et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood 2020; 135 (22): 1929–1945. doi: 10.1182/blood.2019003507.
2. Goyal G, Young JR, Koster MJ et al. The mayo clinic histiocytosis working group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc 2019; 94 (10): 2054–2071. doi: 10.1016/j.mayocp.2019.02.023.
3. Řehák Z, Stejskal V, Adam Z et al. Rozdíly v zobrazení Erdheimovy-Chesterovy choroby FDG-PET/CT, NaF-PET/CT vyšetřením a scintigrafií skeletu. Ústup nemoci po léčbě kladribinem s cyklofosfamidem a anakinrou. Popis případu a přehled symptomů nemoci. Klin Onkol 2026; 39 (3): 199–211. doi: 10.48095/ccko2026199.
4. Peyronel F, Haroche J, Campochiaro C et al. Epidemiology and geographic clustering of Erdheim-Chester disease in Italy and France. Blood 2023; 142 (24): 2119–2123. doi: 10.1182/blood.2023021670.
5. Tessier S, Abeykoon JP, Ruan G et al. Histio-Care Network. Epidemiology of Erdheim-Chester disease in the United States: a SEER-based analysis. Blood Neoplasia 2025; 3 (1): 100188. doi: 10.1016/j.bneo.2025.100188.
6. Kirchner J, Hatzoglou V, Buthorn JB et al. F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: results from 50 patients in a registry study. Eur J Nucl Med Mol Imaging 2021; 48 (4): 1154–1165. doi: 10.1007/s00259-020-05047-8.
7. Aswani Y, Patel A, Zhan X et al. Imaging in Erdheim--Chester disease. Radiographics 2024; 44 (9): e240011. doi: 10.1148/rg.240011.
8. Řehák Z, Koukalová R, Vašina J et al. 18F-FDG PET/CT obraz Erdheimovy-Chesterovy nemoci – přehled českých pacientů. Nukl Med 2018; 7 (3): 50–52.
9. Aouba A, Georgin-Lavialle S, Pagnoux C et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010; 116 (20): 4070–4076. doi: 10.1182/blood-2010-04-279240.
10. Tran TA, Pariente D, Lecron JC et al. Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs. Arthritis Rheum 2011; 63 (12): 4031–4032. doi: 10.1002/art.30638.
11. Aubert O, Aouba A, Deshayes S et al. Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra. Joint Bone Spine 2013; 80 (2): 206–207. doi: 10.1016/j.jbspin.2012.07.005.
12. Killu AM, Liang JJ, Jaffe AS. Erdheim-Chester disease with cardiac involvement successfully treated with anakinra. Int J Cardiol 2013; 167 (5): e115–117. doi: 10.1016/j.ijcard.2013.04.057.
13. Darstein F, Kirschey S, Heckl S et al. Successful treatment of Erdheim-Chester disease with combination of interleukin-1-targeting drugs and high--dose glucocorticoids. Intern Med J 2014; 44 (1): 90–92. doi: 10.1111/imj.12329.
14. Podestà MA, Graziani G, Reggiani F et al. Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra. Kidney Res Clin Pract 2014; 33 (3): 165–167. doi: 10.1016/j.krcp.2014.07.007.
15. Cohen PR, Kurzrock R. Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma. Dermatol Online J 2014; 20 (1): 21241.
16. Courcoul A, Vignot E, Chapurlat R. Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein. Joint Bone Spine 2014; 81 (2): 175–177. doi: 10.1016/j.jbspin.2013.06.013.
17. Szturz P, Adam Z, Rehák Z et al. Xanthelasma palpebrarum responding to interleukin-1 blockade. Intern Med J 2014; 44 (6): 617–618. doi: 10.1111/imj.12441.
18. Cohen-Aubart F, Maksud P, Saadoun D et al. Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. Blood 2016; 127 (11): 1509–1512. doi: 10.1182/blood-2015-09-672667.
19. Diamond EL, Abdel-Wahab O, Durham BH et al. Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease. Blood 2016; 128 (14): 1896–1898. doi: 10.1182/blood-2016-06-725143.
20. Franconieri F, Deshayes S, de Boysson H et al. Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment. Oncoimmunology 2018; 7 (8): e1450712. doi: 10.1080/2162402X.2018.1450712.
21. Morón-Ocaña JM, Pérez-Gil A. Erdheim-Chester disease BRAF (–) diagnosis through cutaneous manifestations and good response with anakinra treatment. An Bras Dermatol 2024; 99 (5): 745–747. doi: 10.1016/j.abd.2023.02.012.
22. Tomelleri A, Cavalli G, De Luca G et al. Treating heart inflammation with interleukin-1 blockade in a case of Erdheim-Chester disease. Front Immunol 2018; 9 : 1233. doi: 10.3389/fimmu.2018.01233.
23. Tran TA, Pariente D, Guitton C et al. Treatment of Erdheim-Chester disease with canakinumab. Rheumatology (Oxford) 2014; 53 (12): 2312–2314. doi: 10.1093/rheumatology/keu344.
24. Gianfreda D, Nicastro M, Galetti M et al. Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. Blood 2015; 126 (10): 1163–1171. doi: 10.1182/blood-2015-01-620377.
25. Haroche J, Amoura Z. Mtor: a new target in Erdheim-Chester disease? Blood 2015; 126 (10): 1151–1152. doi: 10.1182/blood-2015-07-650796.
26. van Bommel EFH, van der Zijden MA, Smak Gregoor PJH et al. Sirolimus monotherapy for Erdheim-Chester disease. Acta Oncol 2019; 58 (6): 901–905. doi: 10.1080/0284186X.2019.1589648.
27. Dagna L, Corti A, Langheim S et al. Tumor necrosis factor a as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol 2012; 30 (28): e286–290. doi: 10.1200/JCO.2012.41.9911.
28. Cohen-Aubart F, Maksud P, Emile JF et al. Efficacy of infliximab in the treatment of Erdheim-Chester disease. Ann Rheum Dis 2018; 77 (9): 1387–1390. doi: 10.1136/annrheumdis-2017-212678.
29. Jia X, Ning X, Bai Q et al. Combination of adalimumab with lower dose of methylprednisolone in Erdheim-Chester disease with systemic involvement. Acta Oncol 2017; 56 (5): 753–756. doi: 10.1080/0284186X.2016.1276213.
30. Berti A, Cavalli G, Guglielmi B et al. Tocilizumab in patients with multisystem Erdheim-Chester disease. Oncoimmunology 2017; 6 (6): e1318237. doi: 10.1080/2162402X.2017.1318237.
31. Boiten HJ, Libourel EJ. Multifocal sclerotic lesions in Erdheim-Chester disease successfully treated with tocilizumab. Immunotherapy 2025; 17 (13): 913–916. doi: 10.1080/1750743X.2025.2561393.
32. Kulkarni AM, Gayam PKR, Aranjani JM. Advances in understanding and management of Erdheim-Chester disease. Life Sci 2024; 348 : 122692. doi: 10.1016/j.lfs.2024.122692.
33. Adam Z. Hematologické choroby nízkého stupně malignity, standardní léčebné postupy a zhodnocení účinnosti 2-chlordeoxyadenosinu. Brno: Masarykova univerzita 1997. 251 s.
34. Saven A, Figueroa ML, Piro LD et al. 2-Chlorodeoxyadenosine to treat refractory histiocytosis x. N Engl J Med 1993; 329 (10): 734–735. doi: 10.1056/NEJM199309023291013.
35. Myra C, Sloper L, Tighe PJ et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol 2004; 88 (6): 844–847. doi: 10.1136/bjo.2003.035584.
36. Adam Z, Koukalová R, Šprláková A et al. Úspěšná léčcba Erdheimovy-Chesterovy nemoci chemoterapií obsahující 2-chlorodeoxyadenosin. Popis dvou případů a přehled literatury. Vnitr Lek 2011; 57 (6): 576–589.
37. Azadeh N, Tazelaar HD, Gotway MB et al. Erdheim Chester disease treated successfully with cladribine. Respir Med Case Rep 2016; 18 : 37–40. doi: 10.1016/j.rmcr.2016.03.008.
38. Blomstrand L, Thor A, Hagberg H. Erdheim-Chester disease presenting as periodontal disease: experience of treatment with cladribine, interferon-a, local radiotherapy and anakinra. Acta Oncol 2016; 55 (2): 248–250. doi: 10.3109/0284186X.2015.1023463.
39. Perić P, Antić B, Knezević-Usaj S et al. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of langerhans cell histiocytosis. Vojnosanit Pregl 2016; 73 (1): 83–87. doi: 10.2298/vsp140915037p.
40. Goyal G, Shah MV, Call TG et al. Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester disease. JAMA Oncol 2017; 3 (9): 1253–1256. doi: 10.1001/jamaoncol.2017.0041.
41. Tamura S, Kawamoto K, Miyoshi H et al. Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: a case report. J Clin Exp Hematop 2018; 58 (4): 161–165. doi: 10.3960/jslrt.18015.
42. Cao XX, Niu N, Sun J et al. Efficacy of intermediate-dose cytarabine in central nervous system-relapsed wild--type BRAF Erdheim-Chester disease. Ann Hematol 2018; 97 (1): 185–187. doi: 10.1007/s00277-017-3114-7.
43. Braiteh F, Boxrud C, Esmaeli B et al. Successful treatment of Erdheim-Chester disease, a non-langerhans-cell histiocytosis, with interferon-alpha. Blood 2005; 106 (9): 2992–2994. doi: 10.1182/blood-2005-06-2238.
44. Haroche J, Amoura Z, Trad SG et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum 2006; 54 (10): 3330–3336. doi: 10.1002/art.22165.
45. Suzuki HI, Hosoya N, Miyagawa K et al. Erdheim-Chester disease: multisystem involvement and management with interferon-alpha. Leuk Res 2010; 34 (1): e21–e24. doi: 10.1016/j.leukres.2009.07.026.
46. Arnaud L, Hervier B, Néel A et al. CNS Involvement and treatment with interferon-a are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011; 117 (10): 2778–2782. doi: 10.1182/blood-2010-06-294108.
47. Hervier B, Arnaud L, Charlotte F et al. Treatment of Erdheim-Chester disease with long-term high-dose interferon-a. Semin Arthritis Rheum 2012; 41 (6): 907–913. doi: 10.1016/j.semarthrit.2011.11.004.
48. Nakhleh A, Slobodin G, Elias N et al. Rapid progression to cardiac tamponade in Erdheim-Chester disease despite treatment with interferon alpha. Mod Rheumatol 2016; 26 (4): 621–624. doi: 10.3109/14397595.2014.905235.
49. Cao XX, Niu N, Sun J et al. Clinical and positron emission tomography responses to long-term high-dose interferon-a treatment among patients with Erdheim-Chester disease. Orphanet J Rare Dis 2019; 14 (1): 11. doi: 10.1186/s13023-018-0988-y.
50. Lim Y, Yoon SE, Cho J et al. Case report of Erdheim-Chester disease successfully treated with pegylated interferon: a single-center experience. Cancer Res Treat 2023; 55 (3): 1053–1057. doi: 10.4143/crt.2022.1535.
51. Shen KN, Chang L, Niu N et al. Pulmonary Erdheim--Chester disease successfully treated with vemurafenib. Ann Hematol 2024; 103 (2): 673–675. doi: 10.1007/s00277-023-05534-6.
52. Aziz SN, Proano L, Cruz C et al. Vemurafenib in the treatment of erdheim chester disease: a systematic review. Cureus 2022; 14 (6): e25935. doi: 10.7759/cureus.25935.
53. Bozan E, Darçın T, Yaman S et al. An effective treatment in Erdheim Chester disease: vemurafenib: a case report. J Med Case Rep 2023; 17 (1): 426. doi: 10.1186/s13256-023-04153-z.
54. Liu ZZ, Liu WT, Miao HL et al. Efficacy and safety of dabrafenib in Erdheim-Chester disease. Ann Hematol 2025; 104 (11): 5669–5676. doi: 10.1007/s00277-025-06707-1.
55. Yuen CA, Bao S, Aung MS et al. Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report. Per Med 2024; 21 (2): 71–78. doi: 10.2217/pme-2023-0137.
56. Salama H, Fahed Alzayed M, Alharbi KG et al. Erdheim--Chester disease successfully treated with front-line single-agent dabrafenib. Am J Case Rep 2022; 23: e935090. doi: 10.12659/AJCR.935090.
57. Saenz-Ancira S, Higuera-Ornelas J, Bernades-Souza B et al. Heart failure with reduced ejection fraction in a patient with Erdheim-Chester disease on dabrafenib. JACC Case Rep 2024; 29 (12): 102374. doi: 10.1016/j.jaccas.2024.102374.
58. Imashuku S, Kobayashi M, Miyoshi T et al. Delayed neurologic response to dabrafenib and trametinib in the case of mixed histiocytosis (LCH/ECD): case report and literature review. Reports (MDPI) 2026; 9 (1): 18. doi: 10.3390/reports9010018.
59. Goyal G, Reiner AS, Bossert D et al. Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease. Blood 2025; 145 (18): 2100–2103. doi: 10.1182/blood.2024028032.
60. Aaroe A, Kurzrock R, Goyal G et al. Successful treatment of non-langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis. Blood Adv 2023; 7 (15): 3984–3992. doi: 10.1182/bloodadvances.2022009013.
61. Al Bayati A, Plate T, Al Bayati M et al. Dabrafenib and trametinib treatment for Erdheim-Chester disease with brain stem involvement. Mayo Clin Proc Innov Qual Outcomes 2018; 2 (3): 303–308. doi: 10.1016/j.mayocpiqo.2018.05.001.
62. Nordmann TM, Juengling FD, Recher M et al. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both. Blood 2017; 129 (7): 879–882. doi: 10.1182/blood-2016-09-740217.
63. Chang L, Shen KN, Luo YP et al. Langerhans cell histiocytosis with mesenteric involvement successfully treated with trametinib: a rare cause of small intestine obstruction. Int J Hematol 2025; 122 (6): 908–910. doi: 10.1007/s12185-025-04071-4.
54. Imashuku S, Kobayashi M, Miyoshi T et al. Delayed neurologic response to dabrafenib and trametinib in the case of mixed histiocytosis (LCH/ECD): case report and literature review. Reports (MDPI) 2026; 9 (1): 18. doi: 10.3390/reports9010018.
65. Pegoraro F, Cohen-Aubart F, Papo M et al. MEK Inhibitors are effective in Erdheim-Chester disease regardless of MAPK pathway mutations. Leukemia 2025; 39 (6): 1540–1542. doi: 10.1038/s41375-025-02614-6.
66. Aromolo IF, Moltrasio C, Maronese CA et al. Successful treatment of cutaneous-onset Erdheim-Chester disease with cobimetinib and anakinra. Clin Exp Dermatol 2024; 49 (5): 523–525. doi: 10.1093/ced/llae014.
67. Campochiaro C, Tomelleri A, Catamerò F et al. Anakinra improves retention rate of targeted treatments in Erdheim-Chester disease. Rheumatology (Oxford) 2025; 64 (8): 4722–4725. doi: 10.1093/rheumatology/keaf023.
68. Campochiaro C, Cavalli G, Farina N et al. Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. Ann Rheum Dis 2022; 81 (1): e11. doi: 10.1136/annrheumdis-2019-216610.
69. Acosta-Medina AA, Abeykoon JP, Zanwar S et al. Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variants. Leukemia 2025; 39 (4): 991–994. doi: 10.1038/s41375-025-02526-5.
70. Schubert C, Schiffmann I, Farschtschi SC et al. Treatment of cerebral histiocytosis with low dose of cobimetinib: a report of 2 cases. Neurol Neuroimmunol Neuroinflamm 2024; 11 (3): e200233. doi: 10.1212/NXI.0000000000200233.
71. Riancho JA, Hernández JL, González-Vela C et al. Erdheim-Chester disease due to a novel internal duplication of NRAS: response to targeted therapy with cobimetinib. Int J Mol Sci 2023; 24 (20): 15467. doi: 10.3390/ijms242015467.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2026 Issue 4
Most read in this issue
- Treatment of Erdheim-Chester disease from the perspective in 2026
- Evaluation of ice ball size as a function of freezing intensity through computed tomography scans during cryoablation procedures
- Dlouhá cesta k RAS (on) inhibitoru
- IgG4-related disease – treatment with anti-CD20, anti-CD19 antibodies, and other new drugs